story of the week
Fulvestrant + Capivasertib vs Placebo After Relapse or Progression on an Aromatase Inhibitor in Metastatic, ER+ Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Fulvestrant Plus Capivasertib Versus Placebo After Relapse or Progression on an Aromatase Inhibitor in Metastatic, Oestrogen Receptor-Positive Breast Cancer (FAKTION): A Multicentre, Randomised, Controlled, Phase 2 Trial
Lancet Oncol 2020 Feb 05;[EPub Ahead of Print], RH Jones, A Casbard, M Carucci, C Cox, R Butler, F Alchami, TA Madden, C Bale, P Bezecny, J Joffe, S Moon, C Twelves, R Venkitaraman, S Waters, A Foxley, SJ HowellFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.